SynthesisGut and liver2022
Accuracy of Noninvasive Scoring Systems in Assessing Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Synthesis in Gut and liver, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 4 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Global prevalence of advanced fibrosis in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.Journal of gastroenterology and hepatology · 2024Pooled it
- KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease.Clinical and molecular hepatology · 2024Guideline
- Diagnostic accuracy of the Fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: A systematic review and meta-analysis.Clinical and molecular hepatology · 2024Pooled it
- Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis.Clinical and molecular hepatology · 2024Pooled it
- Cut or Count? Evaluating Advanced Fibrosis Assessment Tools in MASH and Chronic Viral Hepatitis.Biomedicines · 2026Article
- Article
- Performance of three clinical scores for steatosis and steatohepatitis and their interaction with metabolic syndrome in obese individuals.World journal of hepatology · 2026Article
- Population estimates, trends, characteristics and prognostic outcomes of cardiovascular-kidney-liver-metabolic health: A population-based study.American journal of preventive cardiology · 2026Article
- Article
- Noninvasive liver fibrosis assessment in metabolic dysfunction-associated steatotic liver disease.World journal of hepatology · 2026Review
- FibroX: a machine learning model for detecting and prognosticating advanced fibrosis in metabolic dysfunction-associated steatotic liver disease.Translational gastroenterology and hepatology · 2026Article
- A high FIB-4 score may be an early sign of severe liver involvement in patients with primary antibody deficiencies.Turkish journal of medical sciences · 2026Article
- Validation of BMP8A fibrosis score to identify patients with metabolic dysfunction-associated steatohepatitis with advanced liver fibrosis.Biomarker research · 2025Article
- Population-Based Study on the Coexistence of Metabolic Dysfunction-Associated Steatotic Liver Disease and Chronic Kidney Disease.Journal of the American Heart Association · 2025Article
- Evaluation of Nomenclature of Fatty Liver Disease in Association with Hepatocellular Carcinoma: A 14.5-Year Cohort Study in Korea.Cancer research and treatment · 2025Article
- Response.Canadian family physician Medecin de famille canadien · 2025Article
- Screening for metabolic-associated fatty liver disease in type 2 diabetes patients using non-invasive scores and ultrasound: a cross-sectional study in Egypt.BMC gastroenterology · 2025Article
- Platelet-derived growth factor receptor-β as a non-invasive biomarker for liver fibrosis prediction in Egyptian diabetic patients with metabolic-associated fatty liver disease.BMC gastroenterology · 2025Article
- Cost-effectiveness of advanced hepatic fibrosis screening in individuals with suspected MASLD identified by serologic noninvasive tests.Scientific reports · 2025Article
- Predicting Fibrosis Stage in MASH: The Role of Total Metabolic Syndrome Score and MMP-1.Medicina (Kaunas, Lithuania) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Several noninvasive scoring systems have been developed to determine the risk of advanced fibrosis in nonalcoholic fatty liver disease (NAFLD). We examined the diagnostic accuracy of the fibrosis-4 (FIB-4) score and NAFLD fibrosis score (NFS) in patients with biopsy-proven NAFLD. Methods: For this meta-analysis, various databases including PubMed (MEDLINE), EMBASE, OVID Medline and the Cochrane Library were systematically searched. After the acquired abstracts were reviewed by two investigators, manuscripts were chosen for a full-text examination. Results: Thirty-six studies evaluating biopsy-proven NAFLD were selected for meta-analysis. A total of 14,992 patients were analyzed. The lower cutoff sensitivity of the FIB-4 score predicting histological fibrosis stage 3 or more (≥F3) was 69%, with specificity of 64%, positive likelihood ratio (LR+) of 1.96, and negative likelihood ratio (LR-) of 0.47. The low baseline sensitivity of the NFS score predicting ≥F3 was 70%, with a specificity of 61%, LR+ of 1.83, and LR- of 0.48. The area under the receiver operating characteristic curve (AUC) values of the FIB-4 score predicting ≥F3 and ≥F2 were 76% and 68%, respectively. The AUC values of the NFS score predicting ≥F3 and ≥F2 were 74% and 60%, respectively. Conclusions: The FIB-4 or NFS test can be used to predict the degree of liver fibrosis in NAFLD, and the diagnostic accuracy resulted as relatively high in fibrosis stages of F3 or higher.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.